[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nicolaus Copernicus University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100559422","re-and-probiotics-in-mafldnafld-100559422",false,"NCT06563921","RE and Probiotics in MAFLD\u002FNAFLD","PRObiotic Mixed With Exercise THErapy USe in MAFLD (PROMETHEUS in MAFLD)","Study population: Patients diagnosed with non-alcoholic or metabolically mediated fatty liver disease (NAFLD\u002FMAFLD), including the inflammatory form (NASH), confirmed by imaging (ultrasound, MRI-PDFF) or histopathological (liver biopsy) methods.\n\nInclusion criteria:\n\n* Diagnosis of NAFLD\u002FMAFLD or NASH (imaging or histological confirmation of fatty liver disease, e.g., ultrasound, MRI-PDFF, biopsy)\n* Age 18-60 years\n* Ability to understand the study procedures and provide informed consent.\n* Stable clinical condition for at least 3 months prior to study initiation.\n\nExclusion criteria:\n\n* Lack of fluency in English or Polish\n* Significant (structural) limitation of upper and\u002For lower limb mobility\n* Pregnancy or breastfeeding\n* Inability to understand instructions\n* Shift work\n* Participation in any study or research project within the last 3 months\n* Participation in an interventional drug study within the last 3 months\n* Participants with hepatic steatosis and regular alcohol consumption \\> 30 g\u002Fday\n* Individuals with any concomitant liver disease (viral hepatitis, drug-induced liver injury, metabolic\u002Fgenetic diseases (e.g., Wilson's disease))\n* Anticoagulant\u002Fantiplatelet therapy, antithrombotic therapy, immunosuppressive medications, prolonged immunosuppression (e.g., recent cytotoxic chemotherapy, HIV infection with CD4 count \\\u003C 240), antibiotics, corticosteroids, valproic acid, amiodarone, tamoxifen within 3 months prior to study enrollment\n* Use of medications such as steroids, methotrexate, metformin\n* Use of agents such as vitamin E, omega-3 fatty acids, or medications with evidence of an effect on NAFLD (pioglitazone, GLP-1 analogues, dipeptidyl peptidase IV inhibitors, ursodeoxycholic acid)\n* Active or previous history of invasive cancer (excluding curatively treated carcinoma in situ \\[e.g., cervical\\] or benign skin cancer), unless complete remission has been achieved\n* Regular use of probiotic or prebiotic supplements within 3 months prior to study enrollment\n* Known allergy to probiotics\n* History of using an alternative diet within 3 months prior to study enrollment or changing diet during study entry\n* Previous surgery (bariatric surgery, gastric or intestinal resection)\n* Parenteral nutrition (TPN) within the last 6 months\n* Insulin therapy\n* Uncontrolled diabetes\n* Cardiovascular disease (e.g., uncontrolled blood pressure, coronary artery disease, NYHA class III-IV heart failure, severe arrhythmias, orthostatic intolerance)\n* Nervous system disorders\n* Cognitive impairment and dementia\n* Osteoporosis\u002Fosteopenia\n* Active thyroid disease\n* Cushing's syndrome\n* Any implanted battery-powered device (e.g., AICD, pacemaker, cardiac rhythm recorder, cochlear implant)","ALL","18 Years","60 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"NA","This project aims to evaluate the roles of the autonomic nervous system (ANS) and gut microbiota as correlates of clinical improvement in metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD) in response to a therapeutic regimen comprising resistance exercise and probiotic supplementation. The primary objective is to investigate the effects of these non-pharmacological interventions on MAFLD\u002FNAFLD and to identify patient phenotypes based on baseline ANS profiles and gut microbiota composition that predict clinical responses.",[27,28,29],"NASH","NAFLD","MAFLD",[27,29,28,31,32,33,34],"Probiotics","Resistance training","Gut microbiota","Hypertrophy training","NOT_YET_RECRUITING","2026-04-07",{"date":38,"type":39},"2026-04-09","ACTUAL",{"date":41,"type":21},"2026-04-10",{"date":43,"type":21},"2036-04-10",{"name":45,"class":46},"Nicolaus Copernicus University","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100520812","endoscopic-ultrasound--guided-hartmann-reversal-procedure-100520812","NCT06061432","Endoscopic Ultrasound- Guided Hartmann Reversal Procedure","Endoscopic Reconstruction of the Gastrointestinal Tract After Surgical Resection Procedures Within the Large Intestine (Hartmann's Procedure- Modification of the Method Facilitating the Restoration of Gastrointestinal Continuity)","EndoHARP","Inclusion Criteria:\n\n* participants of both sexes aged above 18 years\n* participants, who provided informed consent for such treatment\n* eligibility for Hartmann's procedure according to current medical knowledge based on evidence-based medicine.\n\nExclusion Criteria:\n\n* pregnancy, breastfeeding, or intention to become pregnant during the study\n* contraindications to electrosurgical instruments\n* allergy to any of the materials used in the study\n* participants with advanced cancer in the metastatic stage\n* participants ineligible for restoration of gastrointestinal continuity\n* participants ineligible for surgery\n* participants ineligible for general anesthesia",{"count":56,"type":21},100,[24],"The goal of this clinical trial is to learn about clinical usefulness endoscopic gastrointestinal anastomoses to restore the gastrointestinal continuity in patients with permanent colostomy after Hartmann procedure.\n\nThe main questions it aims to answer are:\n\n* is the endoscopic restore the gastrointestinal continuity procedure effective?\n* is this endoscopic procedure safe?",[60,61,62],"Colorectal Neoplasms","Diverticular Diseases","Inflammatory Bowel Diseases",[64,65,66,67,68,69],"colorectal surgery","endotherapy","anastomosis","endoscopic ultrasound","gastrointestinal continuity","Hartmann procedure","2023-09-24",{"date":72,"type":39},"2023-09-29",{"date":74,"type":21},"2023-12-01",{"date":76,"type":21},"2026-12-31",{"name":45,"class":46},""]